PYX-201 Receives Orphan Drug Designation From the FDA in Pancreatic Cancer

The FDA has granted an orphan drug designation to PYX-201 for the treatment of patients with pancreatic cancer.

Related Keywords

Virginia ,United States ,Laras Sullivan ,Alexander Spira ,Phasei Program ,Johns Hopkins University ,Research Institute ,Pyxis Oncology ,Gastrointestinal Cancer ,News ,Gi Cancer ,Pancreatic Cancer ,Fda ,Yx 201 ,Nct05720117 ,